These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
178 related items for PubMed ID: 15908722
1. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis]. Kopaliani M. Georgian Med News; 2005 Apr; (121):38-42. PubMed ID: 15908722 [Abstract] [Full Text] [Related]
2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study. Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K. Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969 [Abstract] [Full Text] [Related]
3. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Peichl P, Rintelen B, Kumpan W, Bröll H. Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793 [Abstract] [Full Text] [Related]
4. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes]. Overgaard K, Ravn P, Hansen MA, Christiansen C. Ugeskr Laeger; 1993 Aug 02; 155(31):2387-91. PubMed ID: 8346588 [Abstract] [Full Text] [Related]
5. Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. Peichl P, Marteau R, Griesmacher A, Kumpan W, Schedl R, Prosquil E, Fasol P, Bröll H. J Bone Miner Metab; 2005 Aug 02; 23(3):243-52. PubMed ID: 15838628 [Abstract] [Full Text] [Related]
6. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Plosker GL, McTavish D. Drugs Aging; 1996 May 02; 8(5):378-400. PubMed ID: 8935399 [Abstract] [Full Text] [Related]
7. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women. Downs RW, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, Wang L, Smith ME, Gormley GJ, Melton ME. J Clin Endocrinol Metab; 2000 May 02; 85(5):1783-8. PubMed ID: 10843152 [Abstract] [Full Text] [Related]
8. Early effect of nasal salmon calcitonin on the bone marker Crosslaps. Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G. Rheumatol Int; 2006 Feb 02; 26(4):288-91. PubMed ID: 15875189 [Abstract] [Full Text] [Related]
9. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment. Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C. Am J Med; 1990 Jul 02; 89(1):1-6. PubMed ID: 2152594 [Abstract] [Full Text] [Related]
10. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density. Perrone G, Galoppi P, Valente M, Capri O, D'Ubaldo C, Anelli G, Zichella L. Gynecol Obstet Invest; 1992 Jul 02; 33(3):168-71. PubMed ID: 1612530 [Abstract] [Full Text] [Related]
11. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss]. Stĕpán J, Formánková J, Masatová A, Michalský M, Rosenová Z. Cas Lek Cesk; 1997 Apr 16; 136(8):242-8. PubMed ID: 9264868 [Abstract] [Full Text] [Related]
12. [Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis]. Abellán Pérez M, Bayina García FJ, Calabozo M, Carpintero Benítez P, Figueroa Pedrosa M, Fernández Crisóstomo C, García López A, García Pérez S, Mesa Ramos M, Paulino Tevar J. An Med Interna; 1995 Jan 16; 12(1):12-6. PubMed ID: 7718710 [Abstract] [Full Text] [Related]
14. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis. Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L. Rheumatol Int; 2005 Dec 16; 26(2):157-61. PubMed ID: 15660234 [Abstract] [Full Text] [Related]
15. Calcitonin. Silverman SL. Am J Med Sci; 1997 Jan 16; 313(1):13-6. PubMed ID: 9001161 [Abstract] [Full Text] [Related]
16. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P. J Bone Miner Res; 1994 Jan 16; 9(1):69-73. PubMed ID: 8154311 [Abstract] [Full Text] [Related]
18. [Assessment of cortical bone mineral density and biochemical markers of bone metabolism in postmenopausal osteoporosis]. Kopaliani M. Georgian Med News; 2005 May 16; (122):33-6. PubMed ID: 15988079 [Abstract] [Full Text] [Related]
19. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis]. Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, Ianes A, Gennari C. Minerva Endocrinol; 1989 May 16; 14(3):169-76. PubMed ID: 2695815 [Abstract] [Full Text] [Related]
20. Comparison of alendronate, calcitonin and calcium treatments in postmenopausal osteoporosis. Dursun N, Dursun E, Yalçin S. Int J Clin Pract; 2001 Oct 16; 55(8):505-9. PubMed ID: 11695068 [Abstract] [Full Text] [Related] Page: [Next] [New Search]